Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

Coca-Cola

Abbott, J&J, and Coca-Cola all are Dividend Kings, meaning they have a stellar track record of dividend growth. These companies also have solid product portfolios to drive revenue over time.

3 No-Brainer Dividend Stocks to Buy No Matter What the Market Is Doing

UnitedHealth Group

With inflation taking center stage once again, it's becoming clear that consumers are prioritizing wants and needs. One of those “non-discretionary” expenses is healthcare, which makes it a good time to look for healthcare stocks to buy.

September Rally? 3 Healthcare Stocks to Buy Before Liftoff.

Bristol-Myers

Danaher

The pharmaceutical sector will always be a sector in constant evolution and growth. As technology advances, the companies that make life in this sector will always be applying it, as well as implementing new processes, new combinations, and new formulas, always with the aim of being able to make medicines and treatments much more effective and efficient for all of us.

The 3 Best Pharma Stocks to Buy Now: September 2023

Atmos Energy

Cardinal Health

Colgate-Palmolive

Con Ed

J. M. Smucker

We follow the bond market closely at 24/7 Wall St., and for almost a year now there has been an inversion (or difference in yield) between the two-year Treasury paper and the benchmark 10-year note.

8 Dividend Aristocrat Stocks to Buy Now With a Recession (and Inflation) Looming Large in 2024

Abbott's (ABT) recent deal will enable it to create more interconnected solutions to improve the personalization and accuracy of diabetes control.

Abbott (ABT) to Advance Diabetes Care With New Acquisition

There is more to the comparison, and in the sections below, we discuss why we believe that TMO will offer better returns than ABT in the next three years.

Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?

Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that turn data from a continuous glucose monitor (CGM) into clear and reliable insulin dosing recommendations displayed right on the insulin pen cap Acquisition will bring together two leaders in different aspects of diabetes care: CGM and insulin injection support Together, Abbott and Bigfoot will continue to advance technology-driven solutions for making diabetes management even more personal and precise ABBOTT PARK, Ill. and MILPITAS, Calif.

Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes

Shares of Abbott Laboratories have fallen by more than 10% from the high point they reached in July. The company has a remarkable track record of 50 consecutive years of annual dividend raises.

Down 10.3%, Is Abbott Laboratories Stock a Buy on the Dip?

Abbott's (ABT) latest late-breaking data reflects OCT's potential to improve clinical practice related to stent placement.

Abbott's (ABT) New Positive Data Favors OCT in Stent Implantation

Chewy

Chewy is newly profitable and has managed to grow free cash flow even in a difficult environment. Abbott Laboratories' core business produced double-digit growth in the most recent quarter.

2 Incredible Stocks to Buy on the Dip

Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.

Abbott's (ABT) Libre Gains Momentum Amid Low Testing Sales

BERKELEY, Calif.--(BUSINESS WIRE)--Pivot Bio, Inc., a sustainable agriculture company delivering farmers patented crop nutrition technologies that harness the power of nature to reliably and productively grow the food the world needs, has named Chris Abbott as Chief Executive Officer, effective immediately, to build upon the company's success to date. As previously announced, Pivot Bio co-founder and current CEO Karsten Temme will become Chief Innovation Officer. Chris Abbott is an industry lea.

Pivot Bio Names Chris Abbott CEO; Announces FY2023 Results and Expansion of U.S. Operations

Walmart

Fear is back in the air. On August 8, 2023, Moody's rating agency downgraded central U.S. banks due to weaker profits and increased funding risks.

U.S. Credit Rating Concerns? Here Are 3 Stocks to Protect Your Portfolio

Boston Scientific

Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.

Which Is A Better Buy – Boston Scientific Stock Or Abbott?

Abbott Labs is positioned to recover from sharply lower demand for its COVID-19 tests. Other products like its FreeStyle Libre continuous glucose monitor should help rev up results.

Want Growing Passive Income? This Dividend King Could Be a Smart Buy

Altria

Altria is aiming to have its smoke-free portfolio bringing in $5 billion in revenue by 2028. 3M has increased its yearly dividend for 65 straight years.

Down 4% to 17%, These Monster Dividend Stocks Could Be Picking Up Steam

Abbott's (ABT) Alinity h-series not only delivers technological innovation but also addresses the realistic challenges faced by modern healthcare systems.

Abbott (ABT) Gains in Core Diagnostics With FDA Nod for Alinity H

Blue chip dividend stocks can be outstanding picks for investors with a long-term outlook. Abbott Laboratories and Bristol Myers Squibb are two top-shelf pharma stocks that stand out from the crowd.

2 Blue Chip Dividend Stocks That Are Top Buys in August

Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport

Regeneron Pharmaceuticals

Both of these companies are proven innovators in a necessary industry. Regeneron has two major products and a solid pipeline to drive excellent results.

2 Top Stocks to Buy in August and Hold Forever

Abbott Labs is one of the most consistent dividend stocks you'll find. It can afford to keep hiking its payout for the foreseeable future.

Does Abbott Laboratories' Dividend Make It a Buy?

AbbVie

Abbott Labs spun off AbbVie in 2013. AbbVie has lost patent protection on its largest selling product Humira. AbbVie has better financial metrics and dividends.

Abbott Labs Vs AbbVie: Which One Is The Best Investment Choice?

S&P Global

Artificial Intelligence (AI) is generating a lot of hype on Wall Street, with investors eager to capitalize on its potential. Companies that have been utilizing AI for years are well-positioned to benefit from its commercial success and heightened interest. Mature companies with data-centric business models, such as Abbott Laboratories and S&P Global, could see significant upside from AI.

Two Dividend Aristocrats With Unappreciated AI Upside

Haemonetics

Stryker

Zimmer Biomet Hlds

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.

4 Medical Product Stocks to Buy Amid Recovering Prospects

Healthcare investing provides opportunities with wide moats and long-term potential in companies like Abbott Laboratories. ABT's four major segments, including Medical Devices and Diagnostic Products, address key health issues and show impressive organic sales growth. With a positive earnings outlook and attractive valuation, ABT offers the potential for long-term outperforming returns in the healthcare industry.

News for Abbott Labs Stock (ABT)